黄芪注射液联合更昔洛韦对小儿巨细胞病毒性肝炎的疗效分析

Effects of astragalus injection combined with ganciclovir in children with cytomegalovirus hepatitis

目的观察并分析黄芪注射液联合更昔洛韦对小儿巨细胞病毒性肝炎的临床疗效。方法选取南阳市第二人民医院2013年1月—2017年6月收治的小儿巨细胞病毒性肝炎患者44例,按照治疗方法分成对照组、观察组,各22例。对照组进行更昔洛韦治疗,观察组在对照组的基础上进行黄芪注射液治疗,两组均治疗4周。比较两组临床疗效的总有效率、血清CMV-IgM转阴率、不良反应发生率。结果观察组的临床疗效总有效率是86.36%,显著高于对照组的63.63%,差异有统计学意义(P<0.05)。观察组血清CMV-IgM转阴率是81.82%,显著高于对照组的40.91%,差异有统计学意义(P<0.05)。观察组患儿的不良反应发生率是13.64%,明显低于对照组的54.55%,差异有统计学意义(P<0.05)。结论黄芪注射液联合更昔洛韦对小儿巨细胞病毒性肝炎的疗效好,安全、可靠,值得临床应用和推广。

Objective To observe and analyze the clinical efficacy of astragalus injection combined with ganciclovir in children with cytomegalovirus hepatitis. Methods Selected 44 patients with cytomegalovirus hepatitis in our hospital from January 2013 to June 2017. All patients were divided into the control group and observation group by treatment methods, each group of 22 cases. The control group was treated with ganciclovir. The observation group was treated with astragalus injection on the basis of the control group. The total effective rate of clinical efficacy, serum CMV-IgM negative rate and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of clinical efficacy of the observation group （86.36%） was significantly higher than that of the control group （63.63%） （P 〈 0.05）. The serum CMV-IgM negative rate of observation group （81.82%） was significantly higher than that in the control group （40.91%） （P 〈 0.05）. The incidence of adverse events in the observation group （13.64%） was significantly lower than that in the control group （54.55%） （P 〈 0.05）. Conclusions The clinical efficacy of astragalus injection combined with ganciclovir in children with cytomegalovirus hepatitis is fine, safe and reliable, worthy of clinical application and promotion.